Fact sheet: BB Biotech

Fund information

Fund name
BB Biotech B USD
Fund company manager
Bellevue Asset Management
Fund type
SIB
Fund manager(s)
Felicia Flanigan
since 31/08/2011
Dr.Tazio Storni
since 31/08/2011
Dallas Webb
since 31/08/2011
Lydia Bänziger
since 02/01/2012
Dr.. Daniel Koller
since 31/03/2009
Fund objective
The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.
Benchmark
Nasdaq Biotech Index
Investment style
Active,Growth
Investment method
Shares

Quick stats

1 Year return

9.11 %

1 Year rank in sector

16/29

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 56.7 m

FE Risk score

238

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    97.5%
  • France
    1%
  • Others
    0.8%
  • Money Market
    0.7%
  • Health Care
    57.7%
  • Pharmaceuticals
    17.1%
  • Healthcare & Medical Products
    15.1%
  • Biotechnology/Medical
    4.7%
  • Others
    4.7%
  • US Equities
    97.5%
  • French Equities
    1%
  • International Equities
    0.8%
  • Money Market
    0.7%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund-8.33 %2.14 %9.11 %0.52 %125.04 %
Sector-4.54 %0.79 %7.8 %12.47 %100.07 %
Rank within sector25 / 3011 / 3016 / 2921 / 266 / 22
Quartile th4 th2 nd3 rd4 th2 nd

Calendar performance

YTD-20172016201520142013
Fund18.81 %-24.69 %7.63 %36.33 %63.75 %
Sector11.8 %-9.92 %7.24 %28.08 %41.03 %
Rank within sector6 / 2929 / 2913 / 266 / 233 / 22
Quartile th1 st4 th2 nd2 nd1 st

Risk statistics

Alpha-5.4
Beta1.6
Sharpe-0.01
Volatility26.31
Tracking error13.84
Information ratio-0.32
R-Squared0.86

Price movement

52 week high483.06
52 week low369.17
Current bid price0
Current offer price0
Current mid price438.61

Holdings by region

  • 97.5% USA
  • 1% France
  • 0.8% Others
  • 0.7% Money Market

Holdings by sector

  • 57.7% Health Care
  • 17.1% Pharmaceuticals
  • 15.1% Healthcare & Medical Products
  • 4.7% Biotechnology/Medical
  • 4.7% Others
  • 0.7% Money Market

Holdings by asset type

  • 97.5% US Equities
  • 1% French Equities
  • 0.8% International Equities
  • 0.7% Money Market

Individual holdings

  • 8.3% BIOGEN INC
  • 8.2% GILEAD SCIENCES INC
  • 7.2% AMGEN INC
  • 6.7% REGENERON PHARMACEUTICALS INC
  • 6.4% CELGENE CORP
  • 4.7% ILLUMINA INC
  • 4.4% INCYTE CORP
  • 4.4% VERTEX PHARMACEUTICAL
  • 4.2% ALEXION PHARMACEUTICALS INC
  • 3.3% MYLAN NV